Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer [Yahoo! Finance]
Q32 Bio Inc. (QTTB)
Company Research
Source: Yahoo! Finance
BOSTON April 17, 2024 /PRNewswire/ -- Sensorium Therapeutics (Sensorium), a biotechnology company developing novel, best-in-class medicines to treat a variety of CNS diseases, today announced the appointment of Sam Rasty , Ph.D., as Chief Business Officer. "Sam's expertise will fuel our business development and commercial strategies as we continue to progress our lead programs towards the clinic," said Alexandra Glucksmann , Ph.D., Chief Executive Officer of Sensorium. "Having shepherded product development from discovery to commercialization across pharma and biotech companies of all sizes, he brings deep understanding of the drivers of market dynamics, business development, partnership, and other core activities as we prepare to become a clinical-stage company in early 2025." Dr. Rasty was most recently Chief Executive Officer of Sequence Bio, a genomics and precision medicine company in Canada , President and Chief Executive Officer of PlateletBio, a pioneering cell therapy bi
Show less
Read more
Impact Snapshot
Event Time:
QTTB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QTTB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QTTB alerts
High impacting Q32 Bio Inc. news events
Weekly update
A roundup of the hottest topics
QTTB
News
- Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdatePR Newswire
- Seamless Therapeutics Announces New CEO and Board Chairman to Support US Expansion of Programmable Recombinase Gene Editing Technology Platform [Yahoo! Finance]Yahoo! Finance
- Q32 Bio Inc. (NASDAQ: QTTB) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $50.00 price target on the stock.MarketBeat
- Q32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerPR Newswire
QTTB
Earnings
- 5/9/24 - Miss
QTTB
Sec Filings
- 5/13/24 - Form SC
- 5/9/24 - Form 424B3
- 5/9/24 - Form 10-Q
- QTTB's page on the SEC website